BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M

BIOCRYST PHARMACEUTICALS INC

2025-Q2 EPS reported $0.02 revenue$308,887,000

Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).
Operating income $29.8M (up from $8.8M); non-GAAP op income $57.0M (up from $21.9M).
Net income $5.1M ($0.02 EPS) vs net loss $12.7M ($0.06 loss) in Q2 2024.
Made additional $50M term debt paydown in July; plans to retire remaining $199M with proceeds from European ORLADEYO sale expected to close early Oct.
Full-year 2025 ORLADEYO revenue guidance maintained at $580M-$600M; pipeline on track for data in two programs by year-end.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.